Trials / Completed
CompletedNCT01469182
A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)
A 28-Day Study Evaluating the Safety of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet (SCH 39641/MK-3641) Treatment in Ragweed Allergic Adults (Phase 3, Protocol No.P05751)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 914 (actual)
- Sponsor
- ALK-Abelló A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study assessed the safety profile of short ragweed (Ambrosia artemisiifolia) in participants with ragweed-induced rhinoconjunctivitis with or without asthma. The primary objective was to compare treatment-emergent adverse events (AEs) for participants treated with short ragweed allergy immunotherapy tablet (AIT) with those treated with placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SCH 39641 | Rapidly dissolving tablet sublingually once daily |
| DRUG | Placebo for SCH 39641 | Rapidly dissolving tablet sublingually once daily |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2012-04-01
- Completion
- 2012-04-01
- First posted
- 2011-11-10
- Last updated
- 2017-03-03
- Results posted
- 2014-06-05
Source: ClinicalTrials.gov record NCT01469182. Inclusion in this directory is not an endorsement.